$9,691 $13,650
Marketable investments 40,520 38,707
Accounts receivable, net 6,630 4,809
Inventories, net 6,069 6,639
Prepaid expenses and other current assets 1,870 1,782
Total current assets 64,780 65,587
Property and equipment, net 3,070 3,000
Other assets 139 140
Total assets $67,989 $68,727
LIABILITIES AND STOCKHOLDERS' EQUITY
Liabilities:
Accounts payable $1,808 $1,341
Accrued liabilities 6,628 6,850
Current portion of deferred revenue 1,582 1,544
Customer deposits 12 18
Total current liabilities 10,030 9,753
Deferred revenue, net of current portion 563 601
Other liabilities 308 255
Total liabilities 10,901 10,609
Stockholders' equity:
Common stock, $0.001 par value:
100,000,000 shares authorized
23,695,617 and 23,605,415 shares issued
and outstanding at March 31, 2008 and
December 31, 2007, respectively 24 24
Additional paid-in capital 100,670 99,588
Deferred stock-based compensation (3) (4)
Accumulated other comprehensive income 143 19
Accumulated deficit (43,746) (41,509)
Total s
'/>"/>
SOURCE Thermage, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1.
Thermage, Inc. to Present at the 10th Annual Needham & Company Growth Conference2.
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients3.
YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 264.
Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering5.
BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.6.
Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets7.
China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results8.
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain9.
Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter10.
ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer11.
Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line